Paul M. Kinsella

Partner

kinsella-paul-m
  • JD, with distinction, Stanford Law School, 1993
  • BA, summa cum laude, Boston College, 1988

Qualifications

  • Massachusetts, 1995
  • California, 1993
  • North Carolina, 2017
  • Boston Magazine “Top Lawyers” (2021)
  • Lawdragon 500 - Leading Dealmakers in America (2021-2022) 
  • IFLR1000 (2019-2022)
  • The Legal 500 (2014-2018, 2020)
  • Chambers USA: America's Leading Lawyers for Business (2011-2021)
  • Chambers Global (2020-2022)
  • The Best Lawyers in America (2006-2012, 2015-2022)
  • Massachusetts Super Lawyers (2006-2021); Rising Star (2005)

Paul M. Kinsella

Partner

Paul advises on business combinations, securities offerings, and governance matters.

Experience

M&A matters include representing:

  • Acceleron in its sale to Merck ($11.5 billion)
  • Wright Medical in its sale to Stryker ($5.4 billion)
  • TESARO in its sale to GSK ($5.1 billion)
  • NxStage in its sale to Fresenius ($2.0 billion)
  • Synageva in its sale to Alexion ($8.9 billion)
  • Cubist in its sale to Merck ($9.5 billion)
  • Genzyme in its sale to Sanofi ($20.1 billion and contingent value rights)
  • Javelin in its sale to Hospira, which, after Javelin initiated litigation, closed on its original terms despite emergence of a contamination issue and which involved Hospira topping a merger agreement between Javelin and Myriad
  • Pfizer in its acquisitions of Medivation ($14 billion), in which Pfizer prevailed in an auction triggered by an unsolicited bid by another pharmaceutical company; Hospira ($17 billion); Trillium ($2.3 billion); and Arena ($6.7 billion)
  • Shire in its acquisitions of Baxalta ($32 billion), which commenced with an unsolicited public proposal shortly following Baxalta’s spin-off from Baxter, and Dyax ($5.9 billion)
  • CIRCOR in its successful defense against a hostile tender offer

Capital markets matters include representing:

  • Novavax in $2.5  billion in equity and convertible note offerings
  • Sarepta in $3.0 billion in equity and convertible note offerings
  • TransMedics in its IPO and a follow-on equity offering
  • Ironwood in its IPO, follow-on equity offerings, and spin-off of Cyclerion
  • Zoetis in the exchange of Zoetis stock ($12.9 billion) for Pfizer stock to split-off Zoetis from Pfizer
  • The lead underwriters in the Vigil Neuroscience IPO
  • The lead underwriters in the Entrada Therapeutics IPO
  • The lead underwriters in a $6.7 billion secondary offering of Regeneron common stock and a $2.0 billion Regeneron investment grade debt offering
  • The lead underwriters in the Elanco Animal Health IPO ($1.7 billion) and the dealer managers in the exchange of Elanco stock for Lilly stock ($8.6 billion)

Publications

  • JD, with distinction, Stanford Law School, 1993
  • BA, summa cum laude, Boston College, 1988

Qualifications

  • Massachusetts, 1995
  • California, 1993
  • North Carolina, 2017
  • Boston Magazine “Top Lawyers” (2021)
  • Lawdragon 500 - Leading Dealmakers in America (2021-2022) 
  • IFLR1000 (2019-2022)
  • The Legal 500 (2014-2018, 2020)
  • Chambers USA: America's Leading Lawyers for Business (2011-2021)
  • Chambers Global (2020-2022)
  • The Best Lawyers in America (2006-2012, 2015-2022)
  • Massachusetts Super Lawyers (2006-2021); Rising Star (2005)
Cookie Settings